Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7152W HIGH $14.53
Volume
275.94 K
Value Traded
2.00 M
Short % Float
6.2%
-2.66%Week
-31.56%1 Month
-22.28%3 Month
-3.34%6 Month
-50.81%5 Year
-50.81%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
339.30 M
EPS (TTM)
-1.86
P/E Ratio
-
Ent. Value
-10.10 M
Total Shares
48.87 M
Float Shares
33.30 M
Insiders
31.89%
Institutions
70.43%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ARTV Catalyst Timeline
Dated clinical, regulatory and corporate events for Artiva Biotherapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Artiva Biotherapeutics, Inc.
116Total events
17Upcoming
17Tier-1 (high impact)
2024 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationAlloNKPresentation
Updated AlloNK plus rituximab data in Sjögren disease presented at ISSjD 2026
Sjögren diseasesource ↗
▲Biomarker DataAlloNKClinical Data
Translational B-cell depletion and reconstitution data for AlloNK plus rituximab
autoimmune diseasessource ↗
▼Equity OfferingCorporate
New employee inducement grants of 288,800 RSUs for 17 new employees
▲Additional DataAlloNKClinical Data
Updated Sjögren disease efficacy data as of July 2, 2026 data cutoff
Sjögren diseasesource ↗
▲Safety Data UpdateAlloNKClinical Data
Updated safety data across 73 Phase 2a basket study patients
Sjögren disease, rheumatoid arthritis, systemic sclerosis and inflammatory myositissource ↗
◆Oral PresentationPresentation
Artiva management fireside chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
◆Oral PresentationAlloNKPresentation
Initial clinical response data in lead autoimmune indication
lead autoimmune indicationsource ↗
▲Oral PresentationAlloNKPresentation
Late-breaking oral presentation of AlloNK plus rituximab in 31 patients with rheumatologic diseases at EULAR 2026
rheumatologic diseasessource ↗
▲Poster PresentationAlloNKPresentation
Poster tour presentation of deep B-cell depletion data at EULAR 2026
rheumatologic diseasessource ↗
▲RMATAlloNKDesignation
FDA granted RMAT designation to AlloNK plus rituximab for refractory RA
refractory rheumatoid arthritissource ↗
◆Late-BreakerAlloNKPresentation
Late-breaking oral presentation of AlloNK + rituximab clinical responses in 31 patients with rheumatologic diseases
rheumatologic diseasessource ↗
◆Poster PresentationAlloNKPresentation
Poster view: Robust and durable clinical responses with AlloNK + rituximab in severe RA
rheumatoid arthritissource ↗
◆Oral PresentationPresentation
Artiva management to participate in fireside chat at 2026 Jefferies Global Healthcare Conference
◆Oral PresentationAlloNKPresentation
Oral presentation of AlloNK + rituximab in first patient with severe Sjögren disease
Sjögren diseasesource ↗
◆FDA Feedback ReceivedAlloNKFDA Meeting
Prepare to receive FDA feedback on potential pivotal trial
autoimmune diseasessource ↗
◆Topline ReadoutAlloNKClinical Data
Share clinical efficacy data in rheumatoid arthritis
rheumatoid arthritissource ↗
◆Oral PresentationAlloNKPresentation
Publication only: AlloNK + anti-CD20 safety profile and B-cell depletion comparable to CAR T
immune-mediated diseasessource ↗
◆Poster PresentationAlloNKPresentation
Poster presentation at EULAR 2026: POS1177
rheumatoid arthritissource ↗
◆Management ChangeCorporate
Appointment of Diego Miralles, M.D. as President and Head of Research and Development
▼Equity OfferingCorporate
Pricing of $300 million underwritten offering of common stock and pre-funded warrants
▲FDA Feedback ReceivedAlloNKFDA Meeting
FDA alignment on single registrational trial design for AlloNK in refractory RA
rheumatoid arthritissource ↗
◆Oral PresentationPresentation
Artiva management to participate in panel and fireside chat at 25th Annual Needham Virtual Healthcare Conference
▲Topline ReadoutAlloNKClinical Data
Initial clinical data: 71% ACR50 response in refractory RA patients with at least six months follow-up
rheumatoid arthritissource ↗
◆Trial InitiationAlloNKTrial
Initiate Phase 3 registrational trial of AlloNK plus rituximab in refractory RA
refractory rheumatoid arthritissource ↗
◆Oral PresentationPresentation
Artiva management to participate in fireside chat at TD Cowen 46th Annual Health Care Conference
◆Poster PresentationAlloNKPresentation
Poster presentation on continued durability of AlloNK in NHL
Non-Hodgkin Lymphomasource ↗
◆FDA Feedback ReceivedAlloNKFDA Meeting
FDA regulatory interactions to align on pivotal trial design for AlloNK in refractory RA
refractory rheumatoid arthritissource ↗
◆Topline ReadoutAlloNKClinical Data
Clinical response data from >15 refractory RA patients in 1H 2026
refractory rheumatoid arthritissource ↗
▲Oral PresentationAlloNKPresentation
Clinical, safety and translational data for AlloNK presented at EULAR 2026
refractory rheumatoid arthritis, Sjögren disease, systemic sclerosissource ↗
▲RMATAlloNKDesignation
FDA granted RMAT designation to AlloNK plus rituximab for refractory RA
refractory rheumatoid arthritissource ↗
▲PublicationAlloNKPresentation
First peer-reviewed manuscript on AlloNK published in Cytotherapy
B-cell-driven autoimmune diseasesource ↗
◆Oral PresentationAlloNKPresentation
Initial safety and translational data for AlloNK + mAb across multiple autoimmune diseases and lead indication disclosure
autoimmune diseasessource ↗
◆Timing GuidanceAlloNKPresentation
Initial safety and translational data for AlloNK + mAb across multiple autoimmune indications and lead indication disclosure by year-end 2025
autoimmune diseasessource ↗
◆Oral PresentationAlloNKPresentation
Virtual event discussing initial safety and translational data for AlloNK in combination with anti-CD20 antibodies across autoimmune diseases
autoimmune diseasessource ↗
▲Full ResultsAlloNKClinical Data
Initial safety and translational data for AlloNK + anti-CD20 mAb in autoimmune disease
autoimmune diseasesource ↗
▲Fast Track DesignationAlloNKDesignation
FDA Fast Track Designation for AlloNK in refractory RA
refractory rheumatoid arthritissource ↗
◆Oral PresentationAlloNKPresentation
Translational and safety data release in mid-November
autoimmune diseasessource ↗
▲Fast Track DesignationAlloNKDesignation
FDA Fast Track Designation for AlloNK in refractory RA
refractory rheumatoid arthritissource ↗
▲Enrollment MilestoneAlloNKTrial
Over 100 patients treated with AlloNK across autoimmune and oncology indications
autoimmune and oncologysource ↗
Past FDA Catalysts and PDUFA Decisions
How ARTV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | AlloNK (AB-101) | Phase 1a data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$135M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 31%
Micro Cap(rank 204 of 657)
Percentile Rank
Artiva Biotherapeutics, Inc. carries a moderate pipeline score (43/100), with $337M risk-adjusted pipeline value, led by AB-101 in Refractory Rheumatoid Arthritis (RA) (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AB-101 Cell therapyNCT06991114 | Refractory Rheumatoid Arthritis (RA) | Phase 2 | RECRUITING | 90 | Jan 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every ARTV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AlloNK Fast TrackRMAT | refractory rheumatoid arthritis | Phase 2a | 2026-10-02 | patients with RA: 20; patients with Sj D: 11; patients with SSc: 5; patients with RA follow up: 10Read More | Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Aslan FredDirector, Officer (Chief Executive Officer) | Sell | -23,463 1,519,606 held | $7.20 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ARTV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.5 % (114.3 %) | 174.17 M | 17.96 M | 82.23% ( 8.10 M) |
ARTV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ARTV ranks across every disease it competes in
Competitive Position is a premium feature
See how ARTV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialARTV News
ARTVArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
Artiva Biotherapeutics has announced multiple presentations at ACR Convergence 2026, showcasing updated clinical data from its AlloNK program. The data includes results from patients with refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis. A live webcast is scheduled to discuss these findings and the upcoming Phase 3 registrational trial for AlloNK.
Read more →ARTVArtiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)
Artiva Biotherapeutics presented updated data on AlloNK® for Sjögren disease at the ISSjD 2026. The study showed significant improvements in disease activity and symptoms in patients after six months of treatment. Safety data indicated no serious adverse events related to AlloNK, supporting its outpatient administration potential.
Read more →ARTVArtiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Artiva Biotherapeutics announced that updated clinical data for its AlloNK therapy will be presented at the 17th International Symposium on Sjögren’s Disease. The therapy, aimed at treating refractory rheumatoid arthritis and other autoimmune diseases, has shown promising results in initial trials. Artiva plans to initiate a Phase 3 trial for AlloNK in late 2026.
Read more →ARTVArtiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Artiva Biotherapeutics will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24, 2026. The company is advancing its AlloNK therapy into a Phase 3 trial for refractory rheumatoid arthritis. Initial data indicates promising results in treating autoimmune diseases, enhancing the potential for outpatient administration.
Read more →ARTVArtiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Artiva Biotherapeutics announced plans to initiate a Phase 3 trial for its AlloNK therapy in refractory rheumatoid arthritis (RA) in the second half of 2026. The company expects to disclose updated clinical data from ongoing trials involving patients with RA, Sjögren disease, and systemic sclerosis. The trial aims to evaluate the efficacy of AlloNK combined with rituximab compared to rituximab alone.
Read more →ARTVArtiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
Artiva Biotherapeutics announced its participation in two upcoming investor conferences in September 2026, where management will engage in live fireside chats. The company is also preparing to initiate a Phase 3 trial for its lead program, AlloNK, aimed at treating refractory rheumatoid arthritis. Initial data suggests promising results for AlloNK in various autoimmune diseases.
Read more →ARTVArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported strong second quarter results, highlighting the potential of its AlloNK therapy for treating refractory rheumatoid arthritis. The FDA granted RMAT designation for AlloNK plus rituximab, supporting its Phase 3 trial initiation planned for late 2026. Financially, Artiva is well-positioned with significant cash reserves to fund ongoing operations and trials.
Read more →ARTV▲ +8%on this news
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Artiva Biotherapeutics has approved new employee inducement grants totaling 288,800 restricted stock units for 17 new hires. These grants, which are part of the company's 2025 Inducement Plan, will vest over four years. The move is in compliance with Nasdaq listing Rule 5635(c)(4) and reflects Artiva's commitment to attract talent as it advances its clinical programs.
Read more →ARTVArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Artiva Biotherapeutics will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company is focused on developing AlloNK, a cell therapy for autoimmune diseases, and plans to initiate a Phase 3 trial for refractory rheumatoid arthritis later this year. Initial data suggests promising results for AlloNK in various autoimmune conditions.
Read more →ARTVArtiva Biotherapeutics Highlights AlloNK Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Artiva Biotherapeutics presented promising data for its AlloNK therapy at EULAR 2026, showing significant clinical efficacy in patients with refractory rheumatoid arthritis and other autoimmune diseases. The FDA has granted AlloNK RMAT designation, which supports faster development and review due to its potential effectiveness. The clinical trials reported compelling responses across multiple patient groups, highlighting AlloNK's safety and its capability for outpatient administration. A virtual webcast featuring additional insights into the data will be held today.
Read more →ARTVArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Artiva Biotherapeutics announced its participation in the 2026 Jefferies Global Healthcare Conference, scheduled for June 4, 2026. The company will discuss its lead program, AlloNK, which is being evaluated in clinical trials for autoimmune diseases. Artiva plans to initiate a Phase 3 trial for AlloNK in refractory rheumatoid arthritis later this year.
Read more →ARTV▼ -7.3%on this news
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
Artiva Biotherapeutics has appointed Diego Miralles, M.D., as President and Head of Research and Development. With over 20 years of experience, Dr. Miralles will lead the advancement of AlloNK, a cell therapy for autoimmune diseases, particularly refractory rheumatoid arthritis. The company is preparing for a Phase 3 trial and aims for a BLA submission by 2029.
Read more →ARTV▼ -7.3%on this newsshared move
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases
Artiva Biotherapeutics announced multiple data presentations at the EULAR 2026 Congress, showcasing the efficacy of AlloNK in treating rheumatologic diseases. A late-breaking oral presentation highlighted a 71% ACR50 response in refractory rheumatoid arthritis patients. The data suggests AlloNK's clinical responses are comparable to autologous CAR T-cell therapies, with a favorable safety profile.
Read more →ARTV▼ -13%on this news
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Artiva Biotherapeutics has announced the pricing of a $300 million underwritten offering of common stock and pre-funded warrants. The offering includes 23,871,526 shares priced at $11.52 each and is expected to close around May 11, 2026. Proceeds will support the development of their cell therapies for autoimmune diseases, including a Phase 3 trial for AlloNK.
Read more →ARTV▼ -13%on this newsshared move
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported promising initial clinical data for AlloNK in refractory rheumatoid arthritis, achieving a 71% ACR50 response rate. The company has received FDA alignment for a Phase 3 trial evaluating AlloNK plus rituximab. Despite positive developments, Artiva reported a net loss of $23.5 million for Q1 2026, highlighting ongoing financial challenges.
Read more →ARTV▼ -13%on this newsshared move
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
Artiva Biotherapeutics announced promising initial clinical data for AlloNK in treating refractory rheumatoid arthritis (RA), showing a 71% ACR50 response rate in patients. The FDA has aligned with Artiva on a Phase 3 registrational trial set to begin in 2026, evaluating AlloNK combined with rituximab. The treatment demonstrated a favorable safety profile, with no serious adverse events reported.
Read more →ARTV▼ -7.2%on this news
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference where management will engage in a panel and fireside chat. This event is slated for April 15, 2026, and provides an opportunity for Artiva to showcase its clinical-stage biotechnology developments, particularly in cell therapies for autoimmune diseases and cancers. The company is currently evaluating its lead program, AlloNK, in ongoing clinical trials.
Read more →ARTV▲ +6.5%on this news· ran to +25% by day 1shared move
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Artiva Biotherapeutics announced its financial results for 2025 and highlighted progress with its AlloNK program targeting refractory rheumatoid arthritis (RA). Initial clinical response data for AlloNK is expected in the first half of 2026, with promising results potentially paving the way for a pivotal trial. The company boasts a strong balance sheet with sufficient funds to support operations into mid-2027, despite a reported net loss for the year. Leadership changes and FDA interactions are aimed at advancing the AlloNK program further.
Read more →ARTVArtiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Artiva Biotherapeutics will participate in the TD Cowen 46th Annual Health Care Conference on March 4, 2026. The management team will engage in a fireside chat and meet with investors. Artiva focuses on developing cell therapies for autoimmune diseases and cancers, with ongoing clinical trials for its lead program, AlloNK.
Read more →ARTVArtiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant
Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, bringing extensive experience in finance and operations. Huston will support the company's advancement of AlloNK, a promising therapy for autoimmune diseases. The company is also preparing for feedback from the FDA regarding a pivotal trial and plans to share clinical efficacy data soon.
Read more →About Artiva Biotherapeutics, Inc.
Headquarters5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next ARTV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime